Literature DB >> 35197210

Insights into peptidylarginine deiminase expression and citrullination pathways.

Karen Yu1, Paul Proost2.   

Abstract

Peptidylarginine deiminases (PADs) are calcium-dependent enzymes that mediate citrullination, an irreversible post-translational modification (PTM). PAD enzymes have received increasing attention in (patho-)physiology since multi-omics analysis accelerated their expression profiling. Here, we provide a comprehensive overview of PAD expression at the RNA and protein levels, and a list of annotated substrates per PAD isozyme. We discuss novel roles of citrullination in cellular growth, epigenetic regulation, tissue remodeling, inflammation, and cancer in mouse models and humans. Additionally, we cluster similar effects of protein deimination to offer a different perspective and improve our understanding of citrullination in health and disease. Citrullination should no longer be considered as a rare PTM, but as an important regulatory mechanism in physiology and pathology.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  citrullination; histone citrullination; inflammation; neutrophil extracellular trap (NET); peptidylarginine deiminase; rheumatoid arthritis

Mesh:

Substances:

Year:  2022        PMID: 35197210     DOI: 10.1016/j.tcb.2022.01.014

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   21.167


  3 in total

1.  Novel Peptidylarginine Deiminase Type 4 (PAD4) Inhibitors.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-09-06       Impact factor: 4.632

2.  Protein citrullination marks myelin protein aggregation and disease progression in mouse ALS models.

Authors:  Issa O Yusuf; Tao Qiao; Sepideh Parsi; Ronak Tilvawala; Paul R Thompson; Zuoshang Xu
Journal:  Acta Neuropathol Commun       Date:  2022-09-08       Impact factor: 7.578

Review 3.  The role of extracellular traps in ischemia reperfusion injury.

Authors:  Feilong Zhang; Yuqing Li; Jiyue Wu; Jiandong Zhang; Peng Cao; Zejia Sun; Wei Wang
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.